Role of 2-[18F]fluoro-2-deoxyglucose positron emission tomography in preoperative management of solid-type small-sized lung cancer

Annals of Nuclear Medicine

Volumn 27, Issue 6, 2013, Pages 515-522

  Saisho, Shinsuke ^a   Yasuda, Koichiro ^a   Maeda, Ai ^a   Yukawa, Takuro ^a   Okita, Riki ^a   Hirami, Yuji ^a   Shimizu, Katsuhiko ^a   Nakata, Masao ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

CT; FDG PET; Preoperative staging; Small sized lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; FDGSCAN; FLUORODEOXYGLUCOSE F 18; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE COURSE; FEMALE; HUMAN; INTERMETHOD COMPARISON; LOBECTOMY; LUNG NODULE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SOLID TUMOR;

AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREOPERATIVE PERIOD; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84880845833     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-013-0715-7     Document Type: Article

References (23)

1. Gould MK, Kuschner WG, Rydzak CE, Maclean CC, Demas AN, Shigemitsu H, et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med. 2003;139:879-92.
2. Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003;348:2500-7.
3. Kubota K, Murakami K, Inoue T, Saga T, Shiomi S. Additional effects of FDG-PET to thin-section CT for the differential diagnosis of lung nodules: a Japanese multicenter clinical study. Ann Nucl Med. 2011;25:787-95.
4. Kubota K, Murakami K, Inoue T, Itoh H, Saga T, Shiomi S, et al. Additional value of FDG-PET to contrast enhanced-computed tomography (CT) for the diagnosis of mediastinal lymph node metastasis in non-small cell lung cancer: a Japanese multicenter clinical study. Ann Nucl Med. 2011;25:777-86.
5. Kim BT, Lee KS, Shim SS, Choi JY, Kwon OJ, Kim H, et al. Stage T1 non-small cell lung cancer: preoperative mediastinal nodal staging with integrated FDG PET/CT - a prospective study. Radiology. 2006;241:501-9.
6. Yi CA, Lee KS, Kim BT, Shim SS, Chung MJ, Sung YM, et al. Efficacy of helical dynamic CT versus integrated PET/CT for detection of mediastinal nodal metastasis in non-small cell lung cancer. Am J Roentgenol. 2007;188:318-25.
7. Sawabata N, Miyaoka E, Asamura H, Nakanishi Y, Eguchi K, Mori M, et al. Japanese lung cancer registry study of 11,663 surgical cases in 2004. Demographic and prognosis changes over decade. J Thorac Oncol. 2011;6:1229-35.
8. Detterbeck FC, Falen S, Rivera MP, Halle JS, Socinski MA. Seeking a Home for a PET Part 2: defining the appropriate place for positron emission tomography imaging in the staging of patients with suspected lung cancer. Chest. 2004;125:2300-8.
9. Li X, Zhang H, Xing L, Ma H, Xie P, Zhang L, et al. Mediastinal lymph nodes staging by 18F-FDG PET/CT for early stage non-small cell lung cancer: a multicenter study. Radiother Oncol. 2012;102:246-50.
10. Lee SM, Park CM, Paeng JC, Im HJ, Goo JM, Lee HJ, et al. Accuracy and predictive features of FDG-PET/CT and CT for diagnosis of lymph node metastasis of T1 non-small-cell lung cancer manifesting as a subsolid nodule. Eur Radiol. 2012;22:1556-63.
11. Sobin L, Gospodarowicz M, Witterkind C. International Union against Cancer: TNM Classification of Malignant Tumors. 7th ed. New York: Wiley; 2009.
12. Travis WD, Colby TB, Corrin B, Shimosato Y, Brambilla E. Histological typing of tumors of lung and pleura. In: Sobin LH, editor. World Health Organization international classification of tumours. 3rd ed. New York: Springer; 1999. p. 21-47.
13. Sanli M, Isik AF, Zincirkeser S, Elbek O, Mete A, Tuncozgur B, et al. Reliability of positron emission tomography-computed tomography in identification of mediastinal lymph node status in patients with non-small cell lung cancer. J Thoracic Cardiocasc Surg. 2009;138:1200-5.
14. Cheran SK, Herndon JE 2nd, Patz EF Jr. Comparison of whole' body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. Lung Cancer. 2004;44:317-25.
15. van Tinteren H, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ, Stallaert RA, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet. 2002;359:1388-93.
16. Fischer B, Lassen U, Mortensen J, Larsen S, Loft A, Bertelsen A, et al. Preoperative staging of lung cancer with combined PET-CT. N Engl J Med. 2009;361:32-9.
17. Maziak DE, Darling GE, Inculet RI, Gulenchyn KY, Driedger AA, Ung YC, et al. Positron emission tomography in staging early lung cancer: a randomized trial. Ann Intern Med. 2009;151:221-8.
18. Viney RC, Boyer MJ, King MT, Kenny PM, Pollicino CA, McLean JM, et al. Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer. J Clin Oncol. 2004;22:2357-62.
19. Silvestri GA, Gould MK, Margolis ML, Tanoue LT, McCrory D, Toloza E, et al. Noninvasive staging of non-small cell lung cancer: ACCP evidence-based clinical practice guidelines, 2nd edn. Chest. 2007;132:178S-201S.
20. Gregory DL, Hicks RJ, Hogg A, Binns DS, Shum PL, Milner A, et al. Effect of PET/CT on management of patients with non-small cell lung cancer: results of a prospective study with 5-year survival data. J Nucl Med. 2012;53:1007-15.
21. Dinan MA, Curtis LH, Carpenter WR, Biddle AK, Abernethy AP, Patz EF Jr, et al. Stage migration, selection bias, and survival associated with the adoption of positron emission tomography among medicare beneficiaries with non-small-cell lung cancer, 1998-2003. J Clin Oncol. 2012;30:2725-30.
22. Gill RS, Perry T, Abele JT, Bédard EL, Schiller D. The clinical significance of incidental intra-abdominal findings on positron emission tomography performed to investigate pulmonary nodules. World J Surg Oncol. 2012. doi: 10.1186/1477-7819-10-25.
23. Lin M, Ambati C. The management impact of clinically significant incidental lesions detected on staging FDG PET-CT in patients with non-small cell lung cancer (NSCLC): An analysis of 649 cases. Lung Cancer. 2012;76:344-9.